🇺🇸 FDA
Pipeline program

INO-3112 vaccine

EORTC-1411

Phase 2 mab terminated

Quick answer

INO-3112 vaccine for Uterine Cervical Neoplasms is a Phase 2 program (mab) at INOVIO PHARMACEUTICALS, INC. with 1 ClinicalTrials.gov record(s).

Program details

Company
INOVIO PHARMACEUTICALS, INC.
Indication
Uterine Cervical Neoplasms
Phase
Phase 2
Modality
mab
Status
terminated

Clinical trials